Next™ BriefFunctional Ingredients and the Future of Healthy Aging Foods
Buy Now
Meticulous Next™Food and BeveragesNov 2026102 ppMRN-1391

Healthy aging ingredients Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

Brief ID: MRN-1391Format: PDF + Summary DeckDelivery: InstantHorizon: 8-yr horizonSignal: Accelerating
Buy Now · $950
Adoption maturity (indexed)
Mainstream inflection: ~2030
Horizon: 2026–2034 · Signal: Accelerating
8 yrs
Forward horizon
~2030
Mainstream inflection
Accelerating
Signal strength

What This Brief Covers

This Meticulous Next™ brief examines healthy aging ingredients, meaning protein, fibre and bioactive ingredients that food companies use to build products for older adults, muscle health and people taking GLP-1 medicines. It tests how fast large food companies reformulate and launch dedicated brands, and which participants capture value among food companies, ingredient suppliers and funders as demand moves toward smaller, more nutrient dense meals.

Demand has changed quickly. About 12% of US adults, roughly one in eight, were taking a GLP-1 medicine at the end of 2025, double the 6% reported 18 months earlier, according to a trend report in a trade magazine for dietitians. A cross-sectional study cited in the same report found that 72% of users ate less energy than their estimated needs, while only 20% had been referred to a dietitian. The conclusion is that a large and growing group of consumers eats less food and needs more protein and fibre in each serving, which is the commercial case for these ingredients.

Food companies are responding with dedicated brands. Nestlé introduced Vital Pursuit in the United States in May 2024 as its first food brand for GLP-1 users, with frozen bowls, melts and pizzas that are high in protein, a good source of fibre and sized for a smaller appetite. Danone sells Oikos Fusion, a cultured dairy drink that combines higher protein with prebiotic fibre. The conclusion is that large companies treat this as a lasting change in demand and are building ranges and not single products.

Reformulation is the technical limit. Nestlé said in August 2026 that raising protein and fibre while cutting sugar and calories affects texture, sweetness, stability and production cost, and it described a whey protein microgel technology backed by 11 patents for protein drinks. Reported grocery data also show that households with a GLP-1 user cut grocery spending by 5.3% within six months. The conclusion is that suppliers with processing technology that solves taste and texture gain share of a smaller food basket.

The brief treats healthy aging ingredients as an accelerating signal with an eight year horizon to 2034. It identifies which ingredients, regions and operators scale first and what each means for food companies, ingredient suppliers and funders. It is a focused 102-page decision brief that presents an indicative trajectory rather than a segmented market model.

Brief Snapshot
ParameterDetails
Forward horizon2026–2034 (8 years)
Emerging forceHealthy aging ingredients: protein, fibre and bioactive formats for GLP-1 and aging populations
Technology readinessProtein and fibre formats on sale in frozen foods, dairy and drinks; patented processing for protein drinks; bioactive formats at an earlier stage
Indicative market size & forecastThe healthy aging ingredients market, covering protein, fibre and bioactive ingredients sold into foods and beverages positioned for older adults, muscle health and users of GLP-1 medicines, and excluding dietary supplements and general food ingredients, is valued at USD 6–9 billion in 2026 and is projected to reach USD 12.86–19.29 billion by 2034, at a CAGR of 10%
Mainstream inflection~2030, when protein and fibre are default design choices in mainstream ranges
Signal strengthAbout 12% of US adults on GLP-1 medicines, dedicated brands from Nestlé and Danone, and patented protein processing
Primary beneficiariesFood companies with dedicated brands; ingredient suppliers with patented processing; companies with clinical partnerships
Brief length / format102 pages · PDF + executive summary deck · instant delivery

Understanding the Technology

Healthy aging ingredients are protein, fibre and bioactive ingredients that raise the nutrition of each serving, so that older adults and people on GLP-1 medicines get more from smaller portions.

Protein is used to preserve muscle, and fibre, often as prebiotic fibre, is paired with it to support gut health and fullness.

Performance depends on protein and fibre per serving, taste, texture and tolerance, and the cost of reformulation.

Uses are frozen meals, dairy and drinks, bars and snacks, with bioactive formats for muscle and cellular health as a later layer.

The limits are taste and texture, lower total food spending by users, the cost of reformulation and claims rules. The period turns on how many mainstream ranges adopt protein and fibre as default design choices.

Market Outlook

The healthy aging ingredients market, covering protein, fibre and bioactive ingredients sold into foods and beverages positioned for older adults, muscle health and users of GLP-1 medicines, and excluding dietary supplements and general food ingredients, is valued at USD 6–9 billion in 2026 and is projected to reach USD 12.86–19.29 billion by 2034, at a CAGR of 10%.

The 2026 base rests on protein and fibre ingredients sold into products positioned for older adults, muscle health and GLP-1 users, together with early bioactive formats. Growth then follows reformulation of mainstream ranges, new dedicated brands and wider use of bioactives.

The forecast is sensitive to the pace of GLP-1 use, the success of reformulation on taste and texture, and claims rules. Regionally, North America leads on GLP-1 use and brand launches, Europe on dairy and fibre ingredients, and Asia-Pacific on ageing populations.

Scenarios

The base case assumes GLP-1 use keeps rising through 2028 and mainstream ranges are reformulated by 2030. An accelerated case assumes faster growth in use and wide launches by large retailers, bringing the inflection to 2028 and lifting the 2034 value to the top of the range. A delayed case assumes slower use of GLP-1 medicines and consumer resistance to the taste of high protein foods, holding growth at the bottom of the range.

Factors Behind Growth

Growth drivers

  • Growth of GLP-1 use.
  • Ageing populations and muscle health.
  • Shift to smaller, nutrient dense meals.
  • Launches by large food companies.

Enablers

  • Protein and fibre ingredient supply.
  • Processing technology and patents.
  • Dietitian and clinical networks.
  • Retail and food service channels.

Restraints and barriers

  • Taste and texture limits.
  • Lower total food spending by users.
  • Cost of reformulation.
  • Labelling and claims rules.

The Forces at Play

The direction of healthy aging ingredients is set by the use of GLP-1 medicines, ageing populations, demand for protein and fibre, the role of dietitians and clinical guidance, and claims and labelling rules.

Adoption Outlook

How the shift is likely to unfold across three time horizons.

Near term2026–2028
Reformulation and new brands

Core ranges are reformulated and more dedicated brands for GLP-1 users launch.

Mid term2028–2031
Mainstream retail

Healthy aging foods are stocked widely and bioactive formats enter food.

Long term2031–2034
Default design choices

Protein and fibre are default design choices in mainstream ranges.

Latest Strategic Developments

DateDevelopmentTypeSignificance
May 2024Nestlé introduces Vital Pursuit in the United States, its first food brand for GLP-1 users, with frozen bowls, melts and pizzas high in protein and a good source of fibreProduct launchShows a large food company building a dedicated range
Aug 2026Nestlé sets out a GLP-1 strategy built on protein, fibre and nutrient density, including a whey protein microgel technology backed by 11 patentsStrategySignals investment in processing technology for protein drinks

Key Players & Competitive Landscape

The key participants in healthy aging ingredients include Nestlé S.A., Danone S.A., Abbott Laboratories, Glanbia plc, Kerry Group plc, International Flavors & Fragrances Inc., dsm-firmenich AG, Ingredion Incorporated, Roquette Frères, Cargill, Incorporated, Archer-Daniels-Midland Company, Arla Foods amba, Koninklijke FrieslandCampina N.V., Fonterra Co-operative Group Limited, Novonesis A/S, Amazentis SA, Tate & Lyle PLC, Herbalife Ltd., General Mills, Inc., Ajinomoto Co., Inc., Wageningen University & Research, Tufts University, Harvard T.H. Chan School of Public Health, University of Copenhagen, Lausanne Federal Institute of Technology, U.S. Food and Drug Administration, European Food Safety Authority, European Commission, Food Standards Agency, Food Standards Australia New Zealand, Health Canada, Food Safety and Standards Authority of India, Academy of Nutrition and Dietetics, American Society for Nutrition, American College of Lifestyle Medicine, Obesity Medicine Association, The Obesity Society, International Food Information Council and International Dairy Federation.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as healthy aging foods mature.

Nestlé and Danone lead on dedicated brands, Glanbia, Arla Foods and FrieslandCampina lead on protein ingredients, and Ingredion, Roquette and Tate & Lyle lead on fibre. Competitive intensity is moderate in 2026 and rises as mainstream ranges are reformulated.

ArchetypeRepresentative playersPosition in 2026Outlook to 2034
Food and beverage companiesNestlé, Danone, Abbott Laboratories, General Mills, Herbalife, AjinomotoDedicated brands for GLP-1 users and older adultsDesign and sell finished products
Protein and fibre ingredient suppliersGlanbia, Arla Foods, FrieslandCampina, Fonterra, Ingredion, Roquette, Tate & Lyle, Cargill, Archer-Daniels-MidlandProtein and fibre ingredientsSupply ingredients and processing technology
Bioactive and flavour companiesKerry Group, International Flavors & Fragrances, dsm-firmenich, Novonesis, AmazentisBioactives, taste systems and culturesSolve taste and add bioactive function
Universities and research bodiesWageningen University & Research, Tufts University, Harvard T.H. Chan School of Public Health, University of Copenhagen, Lausanne Federal Institute of TechnologyMuscle, ageing and nutrition researchGenerate clinical evidence
Government agencies and regulatorsU.S. Food and Drug Administration, European Food Safety Authority, European Commission, Food Standards Agency, Food Standards Australia New Zealand, Health Canada, Food Safety and Standards Authority of IndiaClaims, labelling and food safetySet claims and labelling rules
Associations and professional bodiesAcademy of Nutrition and Dietetics, American Society for Nutrition, American College of Lifestyle Medicine, Obesity Medicine Association, The Obesity Society, International Food Information Council, International Dairy FederationGuidance for dietitians and industrySet clinical guidance and standards

Where value migrates.

In 2026 value sits with food companies that hold dedicated brands and shelf space, because they own the consumer and the first reformulation. By 2030 it moves toward ingredient suppliers with processing technology that delivers protein and fibre without losing taste and texture, because every brand faces the same limits. By 2034 it settles in integrated nutrition platforms that combine ingredients, clinical evidence and branded products. Margins hold for suppliers with patented processing and narrow for those that sell protein or fibre as commodities.

Who Will Win — and Why

The archetypes best positioned to capture value as the shift matures.

Food companies with dedicated brands

Firms with ranges built for GLP-1 users and older adults and with clear claims.

Ingredient suppliers with patented processing

Firms that supply protein and fibre with good taste and texture.

Companies with clinical partnerships

Firms that work with dietitians and researchers to build evidence.

Regulatory Landscape

JurisdictionMilestoneIndicative timingEffect on adoption
Nutrient content claimsRules on high protein and good source of fibre claimsIn forceDefine what products can say about protein and fibre
Use of GLP-1 terms on labelsGuidance against labels that name GLP-1 medicinesEmergingShapes how products are positioned
Dietary guidance for usersJoint advice from professional bodies on protein and muscleIn forceDirects brands toward protein, fibre and nutrient density
Rules for novel bioactive ingredientsNovel food and ingredient review for bioactivesIn forceSet the timetable for bioactive formats
Front of pack labellingNational schemes that rate sugar, fat and saltEmergingAffect how reformulated products are rated

Investment Signals

The signals converge on demand ahead of proof. About 12% of US adults on GLP-1 medicines, dedicated brands from large food companies and patented protein processing support growth, while taste and texture limits, lower total food spending, reformulation cost and claims rules limit the pace.

Structural limits show where progress could slow: taste and texture, lower total food spending by users, reformulation cost, and labelling and claims rules. The brief therefore tracks four indicators: share of adults using GLP-1 medicines, brand launches, protein and fibre per serving, and grocery spending.

Protein and fibre foods first, then drinks and dairy, then bioactive formats are the expected order of adoption.

Questions This Brief Answers

01What are healthy aging ingredients, and why do they matter?
02What is the market size in 2026, and what is the forecast to 2034?
03What do brand launches and GLP-1 use indicate?
04What factors are driving growth, and what barriers remain?
05Which key participants are active, and which archetypes are positioned to win?
06What are the latest developments?
07How will reformulation and claims rules shape adoption between 2026 and 2034?
08What should food companies, suppliers and investors do now?

Strategic Implications

  • Food companies: reformulate core ranges toward protein, fibre and nutrient density and avoid labels that name GLP-1 medicines.
  • Ingredient suppliers: invest in processing that solves taste and texture and sign supply agreements with brand owners.
  • Investors and funders: back suppliers with patents and customers, and treat lower total food spending as the main risk.
  • Policy makers and regulators: keep claims rules clear for protein and fibre and review novel bioactives on a set timetable.
  • Dietitians and clinicians: guide users on protein, fibre and muscle, and take part in the research that builds evidence.
Analyst Perspective

"When people eat less, every serving has to do more. The ingredient that makes that possible with good taste will earn the margin."

Lead Foresight Analyst
Biotechnology & Life Sciences · Meticulous Next™

Table of Contents

Access & Licensing

A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.

Single Brief
$950
One named user
Full PDF brief
Executive summary deck
One named user
Free outlook update
★ Most Popular
Team License
$1,350
Up to 10 users
Access for 2–10 users
Internal sharing rights
30-minute analyst briefing
Enterprise
$2,150
Organization-wide
Organization-wide access
Unlimited users
Priority analyst access
Custom extracts
Included with
every brief
Analyst-reviewed foresightMulti-signal validationInstant deliveryFree outlook updates

Frequently Asked Questions

Search Market Intelligence

Search across reports, blogs, press releases, and industries